{"id":58015,"date":"2024-02-27T18:12:30","date_gmt":"2024-02-27T18:12:30","guid":{"rendered":"https:\/\/medsname.com\/etibo\/"},"modified":"2026-04-30T10:17:00","modified_gmt":"2026-04-30T10:17:00","slug":"etibo","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/etibo\/","title":{"rendered":"Etibo"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:18px 0;border-radius:4px;\">\n<p style=\"margin:0 0 8px 0;\"><strong>\ud83d\udca1 R\u0103spuns rapid<\/strong><\/p>\n<p style=\"margin:0;\"><strong>Etibo<\/strong> este <strong>lapatinib 250 mg<\/strong>, un <strong>inhibitor dual al tirosin-cinazei HER2\/EGFR<\/strong> pentru cancer de s\u00e2n avansat sau metastatic <strong>cancer de s\u00e2n HER2-pozitiv<\/strong>. Terapie oral\u0103 zilnic\u0103 combinat\u0103 cu capecitabin\u0103 sau alte regimuri, de obicei dup\u0103 e\u0219ecul tratamentului cu trastuzumab (Herceptin). Efecte secundare semnificative includ diaree, erup\u021bii cutanate \u0219i cardiotoxicitate; necesit\u0103 supraveghere atent\u0103 de c\u0103tre oncolog \u0219i monitorizare ECG.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Ce beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate <a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">ale clien\u021bilor<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Medicamentele noastre generice sunt procurate de la produc\u0103tori certifica\u021bi WHO-GMP \u0219i expediate la nivel mondial \u00een ambalaje discrete \u0219i simple \u2014 f\u0103r\u0103 denumirea medicamentului pe exteriorul coletului. Pl\u0103\u021bile cu cardul sunt procesate printr-un procesor reglementat (descrierile de pe extrasul de cont includ un procesor de pl\u0103\u021bi cu card reglementat \u2014 niciodat\u0103 \u201cMedsBase\u201d sau numele vreunui medicament). Accept\u0103m \u0219i criptomonede \u0219i transferuri bancare SEPA. Fiecare comand\u0103 este sus\u021binut\u0103 de Politica noastr\u0103 de Asigurare pentru Relivrare.<\/p>\n<div style=\"background:#f4f8fb;border-left:4px solid #2c7cb0;padding:14px 20px;margin:16px 0;border-radius:4px;font-size:0.95em;\">\n<strong>\ud83d\udd12 De ce s\u0103 comanzi de la MedsBase:<\/strong> Aprovizionare verificat\u0103 de la produc\u0103tor original \u00b7 Livrare worldwide \u00b7 Plat\u0103 securizat\u0103 (card de credit, crypto) \u00b7 Evaluat 4.9\u2605 de peste 1.400+ clien\u021bi\n<\/div>\n<h2><strong>Ce este Etibo?<\/strong><\/h2>\n<p>Etibo este un medicament generic marca <strong>lapatinib<\/strong> 250 mg, un inhibitor mic molecular al tirosin-kinazei care \u021binte\u0219te <strong>HER2 (ErbB2)<\/strong> \u0219i <strong>EGFR (ErbB1)<\/strong>. Lapatinib blocheaz\u0103 semnalizarea intracelular\u0103 din avalul acestor receptori, op\u0103rind proliferarea celulelor canceroase HER2-pozitive. Fabricat de Natco Pharma.<\/p>\n<p><strong>Critic:<\/strong> Lapatinibul este un medicament oncologic utilizat doar sub supraveghere specializat\u0103. Nu este un produs general de s\u0103n\u0103tate feminin\u0103. Utiliza\u021bi strict conform protocolului oncologului \u2014 de obicei dup\u0103 dezvoltarea rezisten\u021bei la trastuzumab.<\/p>\n<h2><strong>Utiliz\u0103ri clinice<\/strong><\/h2>\n<ul>\n<li><strong>Cancer de s\u00e2n HER2+ avansat\/metastatic<\/strong>: 1250 mg zilnic (5 comprimate) + capecitabin\u0103 \u2014 dup\u0103 e\u0219ecul tratamentului cu trastuzumab.<\/li>\n<li><strong>Cancer de s\u00e2n HER2+ cu letrozol<\/strong> la femei postmenopauzale cu boal\u0103 metastatic\u0103 ER+\/HER2+.<\/li>\n<li><strong>Nu este indicat<\/strong> pentru terapie adjuvant\u0103 (\u00een stadiul precoce curativ) \u2014 trastuzumab \u00b1 pertuzumab r\u0103m\u00e2n standardul de tratament \u00een aceast\u0103 situa\u021bie.<\/li>\n<\/ul>\n<h2><strong>Cum se administreaz\u0103<\/strong><\/h2>\n<ol>\n<li>Lua\u021bi <strong>1250 mg (5 comprimate) o dat\u0103 pe zi<\/strong>, <strong>cu cel pu\u021bin 1 or\u0103 \u00eenainte sau dup\u0103 mese<\/strong>. Alimentele cresc semnificativ absorb\u021bia \u0219i modific\u0103 parametrii de dozare; consecven\u021ba este important\u0103.<\/li>\n<li>Medicament partener tipic: capecitabin\u0103 2000 mg\/m\u00b2\/zi \u00een zilele 1\u201314 ale unui ciclu de 21 de zile.<\/li>\n<li>Monitorizare ECG \u0219i LVEF la baz\u0103 \u0219i la fiecare 3 luni (risc de cardiotoxicitate).<\/li>\n<li>Gestiona\u021bi diareea proactiv \u2014 adesea grad 1\u20133, frecvent\u0103 \u00een primul ciclu. Loperamid\u0103, hidratare, reducere de doz\u0103 dup\u0103 necesitate.<\/li>\n<li>Evita\u021bi grapefruit, portocale Seville \u0219i inhibitori\/induc\u0103tori CYP3A4.<\/li>\n<\/ol>\n<h2><strong>Efecte Secundare<\/strong><\/h2>\n<p><strong>Foarte frecvente:<\/strong> diaree (60\u201380%), erup\u021bie cutanat\u0103 (40\u201360%), grea\u021b\u0103, v\u0103rs\u0103turi, oboseal\u0103, sindrom m\u00e2n\u0103-picior, eritrodestezie palmo-plantar\u0103 (\u00een combina\u021bie cu capecitabin\u0103).<\/p>\n<p><strong>Semne importante:<\/strong> <strong>hepatotoxicitate<\/strong> (monitoriza\u021bi testele hepatice), <strong>cardiotoxicitate \/ LVEF redus<\/strong> (5\u20136%), prelungire QT, boal\u0103 pulmonar\u0103 intersti\u021bial\u0103 (rar\u0103 dar grav\u0103).<\/p>\n<p><strong>Grave:<\/strong> afec\u021biuni hepatice severe, insuficien\u021b\u0103 cardiac\u0103, reac\u021bii cutanate severe (Stevens-Johnson), toxicitate pulmonar\u0103.<\/p>\n<h2><strong>Cine nu ar trebui s\u0103 ia Etibo<\/strong><\/h2>\n<ul>\n<li>Cancer de s\u00e2n HER2-negativ (ineficient)<\/li>\n<li>Insuficien\u021b\u0103 hepatic\u0103 sever\u0103<\/li>\n<li>Insuficien\u021b\u0103 cardiac\u0103 simptomatic\u0103 sau disfunc\u021bie cardiac\u0103 sever\u0103<\/li>\n<li>Sarcin\u0103 \u2014 teratogen<\/li>\n<li>Inhibitori sau inductori puternici ai CYP3A4 administra\u021bi concomitent f\u0103r\u0103 ajustare de doz\u0103<\/li>\n<\/ul>\n<h2><strong>Interac\u021biuni medicamentoase<\/strong><\/h2>\n<ul>\n<li><strong>Inhibitori puternici ai CYP3A4<\/strong> (ketoconazol, ritonavir, claritromicin\u0103, grapefruit): cresc semnificativ nivelurile de lapatinib.<\/li>\n<li><strong>Inductori puternici ai CYP3A4<\/strong> (rifampicin\u0103, carbamazepin\u0103, fenitoin\u0103, St John\u2019s Wort): reduc nivelurile \u0219i eficacitatea lapatinibului.<\/li>\n<li><strong>PPI, antagoni\u0219ti H2<\/strong>: reduc absorb\u021bia \u2014 evita\u021bi sau administra\u021bi la interval de c\u00e2teva ore.<\/li>\n<li><strong>Warfarin\u0103, digoxin\u0103<\/strong>: pot cre\u0219te nivelurile.<\/li>\n<\/ul>\n<h2><strong>Depozitare<\/strong><\/h2>\n<p>P\u0103stra\u021bi la temperatura camerei (15\u201330 \u00b0C), departe de umiditate. P\u0103stra\u021bi \u00een ambalajul original. Nu l\u0103sa\u021bi la \u00eendem\u00e2na copiilor.<\/p>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3 class=\"wp-block-heading\">C\u00e2nd se utilizeaz\u0103 lapatinib?<\/h3>\n<p>Cancer de s\u00e2n HER2-pozitiv avansat\/metastatic, de obicei dup\u0103 rezisten\u021b\u0103 la trastuzumab (Herceptin). Nu se utilizeaz\u0103 \u00een terapia curativ\u0103 pentru stadiile timpurii.<\/p>\n<h3 class=\"wp-block-heading\">De ce s\u0103 lua\u021bi pe stomacul gol?<\/h3>\n<p>M\u00e2ncarea cre\u0219te absorb\u021bia lapatinibului de 4\u20135 ori, f\u0103c\u00e2nd dozarea impredictibil\u0103. Standardul este postul consistent \u2014 1 or\u0103 \u00eenainte sau dup\u0103 m\u00e2ncare \u2014 la un moment fix \u00een fiecare zi.<\/p>\n<h3 class=\"wp-block-heading\">C\u00e2t de grav\u0103 este diareea?<\/h3>\n<p>Frecvent\u0103, adesea grad 1\u20132; gestionabil\u0103 cu loperamid\u0103 \u0219i hidratare. Diareea grad 3+ poate necesita \u00eentreruperea tratamentului \u0219i reducerea dozei. Raporta\u021bi devreme.<\/p>\n<h3 class=\"wp-block-heading\">Va afecta lapatinib inima mea?<\/h3>\n<p>Aproximativ 5\u20136% dintre pacien\u021bi prezint\u0103 sc\u0103deri asimptomatice ale FEVS. ECG + ecocardiogram\u0103 la baz\u0103 \u0219i la fiecare 3 luni. De obicei reversibil\u0103 prin ajustarea dozei sau \u00eentrerupere.<\/p>\n<h3 class=\"wp-block-heading\">Pot lua lapatinib cu trastuzumab?<\/h3>\n<p>Combina\u021bia lapatinib + trastuzumab este utilizat\u0103 \u00een protocoale specifice. Nu este de rutin\u0103 f\u0103r\u0103 supraveghere oncologic\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Dar fertilitatea?<\/h3>\n<p>Este necesar\u0103 contracep\u021bie eficient\u0103 \u00een timpul tratamentului \u0219i pentru 1 s\u0103pt\u0103m\u00e2n\u0103 dup\u0103 (teratogen). B\u0103rba\u021bii trebuie s\u0103 utilizeze contracep\u021bie eficient\u0103 \u00een timpul \u0219i 3 luni dup\u0103 tratament.<\/p>\n<h3 class=\"wp-block-heading\">De ce este aceasta \u00een categoria S\u0103n\u0103tatea Femeilor?<\/h3>\n<p>Cancerul de s\u00e2n HER2+ afecteaz\u0103 dispropor\u021bionat femeile (de\u0219i rar b\u0103rba\u021bii pot dezvolta cancer de s\u00e2n HER2+). Categorizarea reflect\u0103 popula\u021bia, nu un grup clinic strict.<\/p>\n<h3 class=\"wp-block-heading\">Lapatinibul r\u0103m\u00e2ne op\u021biunea de prim\u0103 linie?<\/h3>\n<p>Pentru boala HER2+ metastatic\u0103 de a doua linie (dup\u0103 trastuzumab), lapatinib + capecitabin\u0103 a fost standardul timp de ani. Op\u021biunile mai noi (T-DM1\/Kadcyla, T-DXd\/Enhertu, tucatinib) l-au \u00eenlocuit \u00een mare m\u0103sur\u0103 \u00een oncologia din \u021b\u0103rile dezvoltate \u2014 lapatinibul r\u0103m\u00e2ne important acolo unde noile agen\u021bi nu sunt disponibili.<\/p>\n<h3 class=\"wp-block-heading\">Produse conexe pentru s\u0103n\u0103tatea femeilor<\/h3>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/tamodex\/\">Tamodex (Tamoxifen 10 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/tamilong\/\">Tamilong (Tamoxifen 20 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/letroheal\/\">Letroheal (Letrozole 2.5 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/duphaston\/\">Duphaston (Dydrogesteron\u0103 10 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/deviry\/\">Deviry (Medroxyprogesteron\u0103 10 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/naprosyn\/\">Naprosyn (Naproxen 250 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/candid-v-gel\/\">Candid-V Gel (Clotrimazole)<\/a><\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 20px;margin:16px 0;border-radius:4px;font-size:0.9em;\">\n<p style=\"margin:0;\"><strong>\u2695\ufe0f Disclaimer medical:<\/strong> Informa\u021biile au caracter educativ \u0219i nu \u00eenlocuiesc sfatul medical. Consulta\u021bi un medic \u00eenainte de a \u00eencepe, \u00eentrerupe sau modifica orice tratament, \u00een special pentru terapii oncologice, tratamente hormonale \u0219i produse cu prescrip\u021bie.<\/p>\n<\/div>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Alternative conexe<\/h3>\n<p>Alte medicamente oncologice disponibile \u00eempreun\u0103 cu acest produs:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/verpin\/\">Verpin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/triohale-rotacaps\/\">Triohale Rotacaps<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/inderal\/\">Inderal<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/hydrocl\/\">Hydrocl<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/ezedoc\/\">Ezedoc<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 \u021ainte\u0219te celulele canceroase<br \/>\n\u2705 Inhib\u0103 cre\u0219terea tumorii<br \/>\n\u2705 Trateaz\u0103 cancerul de s\u00e2n<br \/>\n\u2705 Blocheaz\u0103 receptorii HER2<br \/>\n\u2705 \u00cembun\u0103t\u0103\u021be\u0219te ratele de supravie\u021buire<\/p>\n<p>Etibo con\u021bine Lapatinib.<\/p>","protected":false},"featured_media":58016,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3595,3141,3223,3502],"product_tag":[4402,4403],"class_list":{"0":"post-58015","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","9":"product_cat-womens-health","10":"product_tag-etibo","11":"product_tag-lapatinib","13":"first","14":"instock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/58015","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=58015"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/58016"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=58015"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=58015"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=58015"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=58015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}